Fulcrum Therapeutics Gains After Positive Drug Data Spurs $18 Price Target

source:

[1] Bullish Analyst Sentiment on Fulcrum Therapeutics (FULC) Following Positive Updates from Phase 1b PIONEER Study (https://finance.yahoo.com/news/bullish-analys ...)

Fulcrum Therapeutics Gains After Positive Drug Data Spurs $18 Price Target

Related News

BlackSky Stock Gains 80% as Gen-3 Satellite Goes Live

Google's Dual AI Strategy Wins as OpenAI User Growth Stalls

China's $1.076T Trade Surplus Fuels Yuan Appreciation Bets